Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653336 · ClinicalTrials.gov registry record · NA
PerQseal® Clinical Study
A NA study of Percutaneous Large Hole Vascular Closure, sponsored by Vivasure Medical Limited.
- Active
- Registry status
- NA
- Development phase
- 149
- Enrollment target
- 18
- Study locations
NCT05653336: Active NA study of Percutaneous Large Hole Vascular Closure, sponsored by Vivasure Medical Limited.
NCT05653336 is a NA study of Percutaneous Large Hole Vascular Closure that is active but no longer recruiting, run by Vivasure Medical Limited. The registered enrollment target is 149 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05653336, a NA study of Percutaneous Large Hole Vascular Closure, is active but no longer recruiting, sponsored by Vivasure Medical Limited.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 149 participants
- Enrollment target
- 18
- Study locations
Study Summary
The objective is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures.
Primary Outcome
Rate of major access site complications attributable to the PerQseal device
Conditions Studied
Interventions
- DEVICE PerQseal® Closure Device System
Study Locations (18)
New York
- University of Buffalo - Buffalo
- Columbia University Medical Center/ NewYork Presbyterian Hospital - New York
- University of Rochester Medical Center - Rochester
- Stony Brook University Hospital - Stony Brook
- Montefiore Medical Center (multiple centers) - The Bronx
Pennsylvania
- UPMC Pinnacle Health - Mechanicsburg
- UPenn - Perelman Center for Advanced Medicine, - Philadelphia
- Lankenau Institute for Medical Research - Wynnewood
New Jersey
- Cooper University Hospital - Camden
- The Valley Hospital - Paramus
Arizona
- HonorHealth - Scottsdale
California
- Scripps - La Jolla
Maine
- Northern Light Eastern Maine Medical Center - Bangor
Ohio
- The Cleveland Clinic - Cleveland
Texas
- The Texas Heart Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2023-03-30 |
| Est. Completion | 2025-06 |
| Phase | NA |
What the registry record for NCT05653336 still lists
NCT05653336 is an interventional study that assigns participants to a tested intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Percutaneous Large Hole Vascular Closure appearing as the primary indexed condition, and to 1 intervention - of which PerQseal® Closure Device System is the first listed.
NCT05653336 lists 18 locations in 11 states (New York, Pennsylvania, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05653336 about?
NCT05653336 is a clinical study titled "PerQseal® Clinical Study". The objective is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedure...
What is the current status of trial NCT05653336?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 149 participants. The study started on 2023-03-30. Estimated completion is 2025-06.
What conditions does trial NCT05653336 study?
This clinical trial studies the following conditions: Percutaneous Large Hole Vascular Closure.
What interventions are being tested in trial NCT05653336?
The interventions under investigation include: PerQseal® Closure Device System (DEVICE).
Who is sponsoring clinical trial NCT05653336?
This trial is sponsored by Vivasure Medical Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653336 being conducted?
This trial has 18 study locations across Arizona, California, Maine, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05653336's enrollment target sits among peer trials
149 702nd of 2000 higher than 1,299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI